Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, accord
The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft
Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be a close-run thing after the FDA extended the review of a cancer cell therapy cl
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
